RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Relay Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$17.09+0.81 (+4.98%)
Close on Oct 19, 2026
- Market cap
- $3.47B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$10.60 (+163.3%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Relay Therapeutics, Inc. grew revenue 23.9% to $10.35M over the twelve months to Jun 30, 2026. Free cash flow was -$235.87M.
Revenue
$10.35M
+23.9% vs. a year earlier
Operating income
-$310.44M
TTM Q2 2026
Free cash flow
-$235.87M
FY2025
EPS, diluted
-$1.57
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $3.47B
- P/E ratio
- –
- Price to sales
- 334.95
- Price to book
- 3.90
- Dividend yield
- –
- Free cash flow yield
- -6.80%
Fundamentals
- Revenue
- $10.35M
- Net income
- -$286.04M
- EPS, diluted
- -$1.57
- Free cash flow
- -$235.87M
- Book value per share
- $4.39
- Diluted shares
- 203M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$10.35M+23.9% YoY
Operating income
-$310.44M
Net income
-$286.04M
EPS, diluted
-$1.57
Free cash flow
–
Reported periodTrailing twelve months